NEW YORK , Aug. 26, 2024 /PRNewswire/ -- The global breast cancer liquid biopsy testing devices market size is estimated to grow by USD 1.1 billion from 2024-2028, according to Technavio.
The market is estimated to grow at a CAGR of almost 31.34% during the forecast period. Increasing prevalence of breast cancer is driving market growth, with a trend towards technological advances.
However, high costs associated with liquid biopsy testing poses a challenge. Key market players include A. Menarini Industrie Farmaceutiche Riunite Srl, Bio Rad Laboratories Inc.
, Cell Microsystems Inc., Exact Sciences Corp., F.
Hoffmann La Roche Ltd., Guardant Health Inc., Illumina Inc.
, Isogen Life Science BV, Mesa Laboratories Inc., Myriad Genetics Inc., Natera Inc.
, NeoGenomics Laboratories Inc., Novogene Co. Ltd.
, OncoDNA, Pfizer Inc., QIAGEN NV, SAGA Diagnostics AB, Sysmex Corp., and Thermo Fisher Scientific Inc.
. Get a detailed analysis on regions, market segments, customer landscape, and companies- View the snapshot of this report Market Driver The global breast cancer liquid biopsy testing devices market is experiencing significant growth due to advancements in molecular diagnostic products. Breast cancer is linked to specific gene mutations, and the analysis of these mutations is crucial for diagnosis and treatment.
Next-generation sequencing (NGS) in liquid biopsy procedures has revolutionized breast cancer diagnosis. Traditional biopsy methods have limited sensitivity and specificity, m.
